Could a common vasodilator unclog microvessels in septic shock?
NCT ID NCT07657741
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug papaverine can improve blood flow in the smallest blood vessels of people with septic shock. Septic shock causes widespread inflammation and poor circulation, which can damage organs. The trial will give papaverine intravenously to 20 adults in the ICU and measure changes in microcirculation using a camera under the tongue. It is an early pilot study designed to gather safety and physiological data, not to prove treatment effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
papaverine
What this could lead to
If successful, this could point toward a new way to improve blood flow in tiny vessels during septic shock, potentially reducing organ damage.
What could go wrong
This is a very small, early pilot study with only 20 patients and no comparison group. The drug may cause low blood pressure or other side effects, and results may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, 233000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College)
Wuhu, Anhui, 241000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••